22:43 , Jun 29, 2017 |  BC Extra  |  Financial News

Dova rises, Aileron sinks after NASDAQ listings

Rare disease company Dova Pharmaceuticals Inc. (NASDAQ:DOVA) and oncology play Aileron Therapeutics Inc. (NASDAQ:ALRN) each began trading Thursday after pricing IPOs. Dova gained $2.81 (17%) to $19.81 after raising $75.1 million through the sale of...
23:34 , Jun 15, 2017 |  BC Innovations  |  Tools & Techniques

Breaking the barrier

A three-way deal between Amgen Inc. , Feldan Therapeutics Inc. and Elasmogen Ltd. is the latest cause for optimism that technologies are finally converging to enable the generation of cell-penetrating biologics. The biotechs join a...
20:12 , Jun 5, 2017 |  BC Extra  |  Financial News

Dova, Aileron seek NASDAQ listings

Oncology play Aileron Therapeutics Inc. (Cambridge, Mass.) and rare disease company Dova Pharmaceuticals Inc. (Durham, N.C.) each proposed IPOs on NASDAQ. Stapled peptide therapeutic company Aileron filed to raise $69 million in an offering underwritten...
23:34 , May 31, 2017 |  BC Innovations  |  Emerging Company Profile

Stapling β-catenin

Harvard University professor and serial entrepreneur Greg Verdine’s new start-up, FOG Pharmaceuticals Inc. , is using his latest version of stapled peptide technology to block the notoriously undruggable protein, β-catenin , in metastatic colorectal cancer...
08:00 , Dec 17, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Mdm4 p53 binding protein homolog (MDM4; MDMX)

Cancer INDICATION: Cancer; lymphoma In vitro, patient sample and mouse studies suggest antisense oligonucleotides targeting MDM4 exon 6 could help treat cancer. Human melanoma, ovarian, breast, and other cancer cell lines and melanoma tumor samples...
08:00 , Mar 2, 2015 |  BC Week In Review  |  Clinical News

ALRN-6924: Phase I started

Aileron began a dose-escalation, U.S. Phase I trial to evaluate ALRN-6924 in 100-150 patients. Aileron Therapeutics Inc. , Cambridge, Mass.   Product: ALRN-6924   Business: Cancer   Molecular target: Mdm2 p53 binding protein homolog (MDM2)...
08:00 , Feb 12, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: K-Ras (KRAS); son of sevenless homolog 1 (SOS1)

Cancer INDICATION: Cancer In vitro studies have identified stapled peptide-based inhibitors of KRAS that could help treat cancer. In a KRAS binding assay, a stapled peptide based on the α-helix of SOS1 bound wild-type and...
01:56 , Nov 19, 2013 |  BC Extra  |  Financial News

Aileron raises $30 million series E

Aileron Therapeutics Inc. (Cambridge, Mass.) raised $30 million in a series E round. All of the company's existing investors participated, including Apple Tree Partners; Roche Venture Fund; Novartis Venture Funds; Lilly Ventures; SR One; and...